Astria Therapeutics Strikes Licensing Deal in Japan

MT Newswires Live
08/07

Astria Therapeutics (ATXS) said Wednesday it has licensed the development and commercialization rights for its hereditary angioedema drug candidate, navenibart, in Japan to Kaken Pharmaceutical.

The company said it will receive an upfront payment of $16 million, with the potential for an additional $16 million in milestone payments.

Astria said it now expects its cash, cash equivalents and short-term investments will be able to fund its operating plan into 2028.

Shares of Astria were up about 1.7% in recent trading.

Price: 7.14, Change: +0.12, Percent Change: +1.71

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10